New Castle, DE — November 14, 2024 — ABS Bio, Inc., a leader in biospecimen sourcing, cell culture services and biostorage for the global pharmaceutical and biotechnology industry, today announced a strategic investment by 3 Boomerang Capital, a Greenwich, CT based healthcare-focused private equity firm. The investment will position ABS Bio to accelerate enhancements to its service offerings while growing its reach among biopharma R&D professionals. ABS also announced an expanded board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.
Read More
